Abstract:Inflammation has an important role in the development of liver fibrosis in general and the activation of hepatic stellate cells (HSCs) in particular. It is known that HSCs are themselves able to produce cytokines and chemokines, and that this production may be a key event in the initiation of fibrogenesis. However, the direct involvement of cytokines and chemokines in HSC (self-)activation remains uncertain. In this study, the effects of pro-inflammatory cytokines IL-1α and β, TNF-α, and IL-8 on the activation state of HSCs were examined, in comparison to the pro-fibrogenic mediator TGF-β1. LX-2 cells were stimulated for 24 or 48 hours with recombinant human form of the pro-inflammatory cytokines IL-1α and β, TNF-α, and IL-8, and also the pro-fibrogenic mediator TGF-β1. Two drugs were also evaluated, the anti-TNF-α monoclonal antibody infliximab and the IL-1 receptor antagonist anakinra, regarding their inhibitory effects. In LX-2 human HSC, treatment with TGF-β1 are associated with downregulation of the metalloproteinase (MMP)-1 and MMP-3, with upregulation of tissue inhibitor of metalloproteinase (TIMP)-1, collagen type I α1, collagen type IV α1, α-SMA, endothelin-1 and PDGF-BB. Cytokines and chemokines expression were found to be downregulated, excepting IL-6. In contrast, we observed that LX-2 exposure to IL-1, TNF-α and IL-8 can reverse the phenotype of pro-fibrogenic activated cells. Indeed, MMP-1, MMP-3 and MMP-9 were found elevated, associated with downregulation of α-SMA and/or PDGF-BB, and a greater expression of IL-1β, IL-6, IL-8, CXCL1 and CCL2. Lastly, we found that infliximab and anakinra successfully inhibits effects of TNF-α and IL-1 respectively in LX-2 cells. Infliximab and anakinra may be of value in preclinical trials in chronic liver disease. Overall, our results suggest that (i) pro-inflammatory mediators exert complex effects in HSCs via an MMP/TIMP imbalance, and (ii) targeting IL-1 signaling may be a potentially valuable therapeutic strategy in chronic liver diseases.

TIMP-1 in the Process of the Formation and Development of Hepatic Fibrosis Influence

Matrix Metallo-proteinase Inhibitor-1 and Hepatic Fibrosis

Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis

Research progress of liver fibrosis and MMPs and TIMPs

Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63–Integrin Β1 Interaction

Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis

Transforming Growth Factor-Β1 Induced Epithelial-Mesenchymal Transition in Hepatic Fibrosis.

Extracellular Matrix Metabolism and Fibrotic Disease

Growth Factor Family and Hepatic Fibrosis

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

Matrix Mechanics as Regulatory Factors and Therapeutic Targets in Hepatic Fibrosis

Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Deficiency Exacerbates Carbon Tetrachloride-Induced Liver Injury and Fibrosis in Mice: Involvement of Hepatocyte STAT3 in TIMP-1 Production

Relationship Between Matrix Metalloproteinase-1,Tissue Inhibitor of Metalloproteinase-1 and Matrix Transition in Experimental Rat Liver Fibrosis and Influence of Kangxian Ruangan Granule on Them

Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis

TIMP-1 Expression Induced by IL-32 is Mediated Through Activation of AP-1 Signal Pathway.

Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis

Expression of Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Lung Fibrosis of TGF-β1 Transgenic Mice

Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells

Matrix Metalloproteinases, the Pros and Cons, in Liver Fibrosis